Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/171192
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPesini, Alba-
dc.contributor.authorIglesias, Eldris-
dc.contributor.authorBayona Bafaluy, M. Pilar-
dc.contributor.authorGarrido Pérez, Nuria-
dc.contributor.authorMeade, Patricia-
dc.contributor.authorGaudó, Paula-
dc.contributor.authorJimenez Salvador, Irene-
dc.contributor.authorAndrés Benito, Pol-
dc.contributor.authorMontoya, Julio-
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)-
dc.contributor.authorPesini, Pedro-
dc.contributor.authorRuiz Pesini, Eduardo-
dc.date.accessioned2020-10-13T14:41:23Z-
dc.date.available2020-10-13T14:41:23Z-
dc.date.issued2019-10-15-
dc.identifier.urihttp://hdl.handle.net/2445/171192-
dc.description.abstractMany patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de novo pyrimidine biosynthesis pathway connects with the mitochondrial respiratory chain upstream from respiratory complex IV. We hypothesized that these patients would have decreased pyrimidine nucleotide levels. Then, different cell processes for which these compounds are essential, such as neuronal membrane generation and maintenance and synapses production, would be compromised. Using a cell model, we show that inhibiting oxidative phosphorylation function reduces neuronal differentiation. Linking these processes to pyrimidine nucleotides, uridine treatment recovers neuronal differentiation. To unmask the importance of these pathways in Alzheimer disease, we firstly confirm the existence of the de novo pyrimidine biosynthesis pathway in adult human brain. Then, we report altered mRNA levels for genes from both de novo pyrimidine biosynthesis and pyrimidine salvage pathways in brain from patients with Alzheimer disease. Thus, uridine supplementation might be used as a therapy for those Alzheimer disease patients with low respiratory complex IV activity.-
dc.format.extent30 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherImpact Journals Llc-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/aging.102328-
dc.relation.ispartofAging, 2019, vol. 11, num. 19, p. 8433-8462-
dc.relation.urihttps://doi.org/10.18632/aging.102328-
dc.rightscc by (c) Pesini et al., 2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationMalaltia d'Alzheimer-
dc.subject.classificationPirimidines-
dc.subject.otherAlzheimer's disease-
dc.subject.otherPyrimidines-
dc.titleBrain pyrimidine nucleotide synthesis and Alzheimer disease-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2020-10-13T10:20:27Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31560653-
Appears in Collections:Articles publicats en revistes (Institut de Neurociències (UBNeuro))
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PesiniA.pdf3.18 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons